We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Successful Neoadjuvant Therapy with Pembrolizumab Monotherapy for Advanced Ascending Colon Cancer.
- Authors
Chien-Tzu Huang; Jeng-Shiun Du
- Abstract
Immune checkpoint inhibitors have emerged as an effective standard of care for deficient mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (CRC). However, the role of immunotherapy in the neoadjuvant setting remains uncertain. We report a patient with advanced colon cancer who received curative surgery after successful treatment with pembrolizumab monotherapy. She remains in complete remission after 16 months following the first diagnosis without any immune-related adverse events. In conclusion, single-agent pembrolizumab has strong potential in neoadjuvant therapy for patients with dMMR/MSI-H advanced CRC.
- Subjects
NEOADJUVANT chemotherapy; PEMBROLIZUMAB; COLON cancer treatment; CANCER immunotherapy; IMMUNE checkpoint inhibitors
- Publication
Journal of Cancer Research & Practice, 2023, Vol 10, Issue 3, p118
- ISSN
2311-3006
- Publication type
Article
- DOI
10.4103/ejcrp.eJCRP-D-23-00005